drugset / Trial / NCT00118612
Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease. Tree MATA MPL has been developed to provide pre-seasonal specific immunotherapy for patients with an allergy to tree pollen (hay fever). The purpose of this double-blind Phase IIb study is to assess the tolerability and immunogenicity of different doses of Tree MATA MPL in volunteers allergic to birch, hazel and alder pollen.
Timeline
- Start
- 2005-07-07
- Primary completion
- 2005-09-15
- Completion
- 2005-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tree MATA MPL | Other / unclassified | 300 unknown | Subcutaneous |
| Subject | Tree MATA MPL | Other / unclassified | 1600 unknown | Subcutaneous |
| Subject | Tree MATA MPL | Other / unclassified | 4000 unknown | Subcutaneous |